Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

21 oct. 2022 08h51 HE | Source: Allied Market Research

Global Bone Cancer Treatment Market to Reach $1.8 Billion by 2031: Says AMR

Portland, OR, Oct. 21, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Bone Cancer Treatment Market was estimated at $1.2 billion in 2021 and is...
10 mai 2011 16h00 HE | Source: Infinity Pharmaceuticals, Inc.

Infinity Reports First Quarter 2011 Financial Results

— Reaffirms 2011 Financial Guidance and Provides Additional Details — — Anticipates Completion of Patient Enrollment in Phase 2 Trial of IPI-926 in Pancreatic Cancer...
03 avr. 2011 13h36 HE | Source: Infinity Pharmaceuticals, Inc.

Infinity Reports New Preclinical Data for IPI-926 at AACR Supporting Development in Chondrosarcoma

CAMBRIDGE, Mass., April 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results for its novel Smoothened antagonist, IPI-926, in a preclinical...
15 mars 2011 16h00 HE | Source: Infinity Pharmaceuticals, Inc.

Infinity Provides Company Update and Reports Fourth Quarter and Full-Year 2010 Financial Results

IPI-926 Advancing in Two Phase 2 Trials, Underscoring Pipeline Momentum Cash Runway Into 2014 Enables Advancement of Product Candidates to Key Inflection Points Company Changes Accounting...